|
1
|
Ischemic neurons prevent vascular regeneration of neural tissue by secreting semaphorin 3A.
|
Blood
|
2011
|
2.02
|
|
2
|
Carrageenan-induced paw edema in rat elicits a predominant prostaglandin E2 (PGE2) response in the central nervous system associated with the induction of microsomal PGE2 synthase-1.
|
J Biol Chem
|
2004
|
1.67
|
|
3
|
MF63 [2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation.
|
J Pharmacol Exp Ther
|
2008
|
1.23
|
|
4
|
Substituted phenanthrene imidazoles as potent, selective, and orally active mPGES-1 inhibitors.
|
Bioorg Med Chem Lett
|
2007
|
1.05
|
|
5
|
Optimization of a tertiary alcohol series of phosphodiesterase-4 (PDE4) inhibitors: structure-activity relationship related to PDE4 inhibition and human ether-a-go-go related gene potassium channel binding affinity.
|
J Med Chem
|
2003
|
1.03
|
|
6
|
Choroidal involution is a key component of oxygen-induced retinopathy.
|
Invest Ophthalmol Vis Sci
|
2011
|
1.00
|
|
7
|
Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia.
|
J Med Chem
|
2011
|
0.97
|
|
8
|
Cathepsin K null mice show reduced adiposity during the rapid accumulation of fat stores.
|
PLoS One
|
2007
|
0.97
|
|
9
|
Discovery of disubstituted phenanthrene imidazoles as potent, selective and orally active mPGES-1 inhibitors.
|
Bioorg Med Chem Lett
|
2009
|
0.93
|
|
10
|
Pharmacological characterization of a selective COX-2 inhibitor MF-tricyclic, [3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone], in multiple preclinical species.
|
Eur J Pharmacol
|
2007
|
0.92
|
|
11
|
The identification of 4,7-disubstituted naphthoic acid derivatives as UDP-competitive antagonists of P2Y14.
|
Bioorg Med Chem Lett
|
2011
|
0.91
|
|
12
|
Applying the pro-drug approach to afford highly bioavailable antagonists of P2Y(14).
|
Bioorg Med Chem Lett
|
2010
|
0.91
|
|
13
|
5-Lipoxygenase-activating protein homodimer in human neutrophils: evidence for a role in leukotriene biosynthesis.
|
Biochem J
|
2006
|
0.90
|
|
14
|
Synthesis and SAR of pyrimidine-based, non-nucleotide P2Y14 receptor antagonists.
|
Bioorg Med Chem Lett
|
2011
|
0.85
|
|
15
|
Ghrelin modulates physiologic and pathologic retinal angiogenesis through GHSR-1a.
|
Invest Ophthalmol Vis Sci
|
2011
|
0.83
|
|
16
|
Discovery of novel P2Y14 agonist and antagonist using conventional and nonconventional methods.
|
J Biomol Screen
|
2011
|
0.82
|
|
17
|
Trisubstituted ureas as potent and selective mPGES-1 inhibitors.
|
Bioorg Med Chem Lett
|
2011
|
0.79
|
|
18
|
Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors.
|
Bioorg Med Chem Lett
|
2008
|
0.77
|
|
19
|
Biarylimidazoles as inhibitors of microsomal prostaglandin E2 synthase-1.
|
Bioorg Med Chem Lett
|
2010
|
0.77
|
|
20
|
Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment.
|
Bioorg Med Chem Lett
|
2010
|
0.77
|
|
21
|
Restoration of renal function by a novel prostaglandin EP4 receptor-derived peptide in models of acute renal failure.
|
Am J Physiol Regul Integr Comp Physiol
|
2012
|
0.76
|
|
22
|
Lack of clinical efficacy of a phosphodiesterase-4 inhibitor for treatment of heaves in horses.
|
J Vet Intern Med
|
2006
|
0.76
|
|
23
|
Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.
|
Bioorg Med Chem Lett
|
2005
|
0.75
|